Arcus Biosciences, Inc. (RCUS) is a publicly traded Healthcare sector company. As of May 21, 2026, RCUS trades at $23.74 with a market cap of $2.94B and a P/E ratio of -7.37. RCUS moved +4.48% today. Year to date, RCUS is +9.05%; over the trailing twelve months it is +167.64%. Its 52-week range spans $6.50 to $28.72. Analyst consensus is strong buy with an average price target of $35.89. Rallies surfaces RCUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arcus Casdatifan Shows 45% ORR, 15.1-Month PFS and $1B Cash; PEAK-1 Enrollment Underway: Arcus reported updated ARC-20 casdatifan data showing a 45% confirmed ORR and 15.1-month median PFS in late-line ccRCC, versus belzutifan’s 5.6-month PFS. It ended Q4 with $1.0B cash, guided 2026 GAAP revenue of $45–55M, and is enrolling its Phase III PEAK-1 casdatifan plus cabozantinib trial.
| Metric | Value |
|---|---|
| Price | $23.74 |
| Market Cap | $2.94B |
| P/E Ratio | -7.37 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.72 |
| 52-Week Low | $6.50 |
| Volume | 655.90K |
| Avg Volume | 0 |
| Revenue (TTM) | $236.00M |
| Net Income | $-369.00M |
| Gross Margin | 0.00% |
10 analysts cover RCUS: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.89.